JCVI

The ‘jab market’ of private COVID vaccines is a good thing for public health – but not for health inequality

Retrieved on: 
Thursday, February 15, 2024

Yes.

Key Points: 
  • Yes.
  • Yes.

What are the benefitS?

  • That’s because the more people that are able to keep up to date with COVID boosters, the higher the level of immunity across the population.
  • High booster coverage can help protect against surging cases or potential new variants, and help lower levels of COVID-related sickness across the population.
  • Crucially, though, increased booster coverage could help reduce rates of long COVID – the risk of which rises with multiple re-infections .

But will people buy them?

  • Along with colleagues, last year I conducted research on attitudes to private COVID boosters in Wales.
  • If the private market for the flu jab is anything to go by, then ease of access might give COVID uptake rates a boost.
  • Ultimately it remains to be seen how much demand there will be for private COVID vaccines.

Private vaccines could worsen health inequalities

  • At a price of £45 per jab, those on low income are much less likely to be able to afford them.
  • As such, the private sale of COVID vaccines will only serve to perpetuate health inequalities.
  • They are also more likely to be negatively impacted by winter pressures and health service crises.

People should be free to choose to get vaccinated

  • Vaccine passports and mandatory vaccination for health and social care workers were strongly opposed by some on the grounds that they took away people’s choice to not get vaccinated.
  • Surely the same arguments made against requiring people to get vaccinated should also apply to excluding people from getting vaccinated?


Simon Nicholas Williams has received funding from Senedd Cymru, Public Health Wales and the Wales Covid Evidence Centre for research on COVID-19, and has consulted for the World Health Organization. However, this article reflects the views of the author only, in his academic capacity at Swansea University, and no funding or organizational bodies were involved in the writing or content of this article.

BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform

Retrieved on: 
Thursday, October 5, 2023

GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company’s proprietary AI-driven platform, bfLEAP™. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution. JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.

Key Points: 
  • The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution.
  • JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
  • “TCGA has been extensively analyzed by scientists for more than a decade, yet in a matter of weeks, we were able to identify multiple new drug target candidates with previously undocumented potential in colorectal cancer from this same dataset,” stated Vin Singh, Chairman and CEO of BullFrog AI.
  • "These findings demonstrate the power and potential of our bfLEAP™ platform, which combines advanced AI algorithms with rich biological data to identify novel targets for a wide range of diseases.

Artistic Fashion Designs from Wilder Blue Planet Helping Clean Up Oceans

Retrieved on: 
Tuesday, November 8, 2022

She found that supporting a cause through fashion especially unique, artistic, designs and e-commerce shopping were the trends in vogue.

Key Points: 
  • She found that supporting a cause through fashion especially unique, artistic, designs and e-commerce shopping were the trends in vogue.
  • So, the two combined their expertise and insights and created Wilder Blue Planet to do just that.
  • Wilder Blue Planet sources from suppliers that are environmentally and sustainability conscious.
  • The website offers artistic apparel and accessories and complete information about the company's mission, products, and philanthropic goals.

Global Shingles Vaccine Market to 2028 - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 12, 2022

Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth.

Key Points: 
  • Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth.
  • The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines.
  • For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013.
  • Chapter 3 Shingles Vaccine Market Variables, Trends & Scope
    3.4.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)

J. Craig Venter Institute Scientists to Investigate Role of Opioid Abuse in HIV and HIV-Associated Neurocognitive Disorders Pathogenesis through $4.7M NIDA Grant

Retrieved on: 
Thursday, February 25, 2021

Opioid misuse is a route of contracting HIV and a barrier to effective antiretroviral therapy (ART).

Key Points: 
  • Opioid misuse is a route of contracting HIV and a barrier to effective antiretroviral therapy (ART).
  • However, it is unclear whether opioid misuse changes the course of HIV pathogenesis, especially on HAND.
  • Funding for this work is provided by the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), grant 7UM1DA051411-02.
  • The J. Craig Venter Institute (JCVI) is a not-for-profit research institute in Rockville, Maryland and La Jolla, California.

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research

Retrieved on: 
Saturday, August 15, 2020

The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome.

Key Points: 
  • The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome.
  • View the full release here: https://www.businesswire.com/news/home/20200814005092/en/
    Dr. John Craig Venter, recipient of the 2020 - Edogawa NICHE Prize, for his contribution to research and development pertaining to the Human genome.
  • Alumni of the Fujio Cup Quiz, a part of NCRM NICHE, ( www.ncrmniche.org ), have priority for nomination, a unique feature of this prize.
  • He has founded Celera Genomics, The Institute of Genomic Research (TIGR), J.Craig Venter Institute (JCVI) and co-founded Human Longevity Inc and Synthetic Genomics.

J. Craig Venter Institute and UC San Diego Develop Phage Treatment as Potential Cure for Alcoholic Liver Disease

Retrieved on: 
Wednesday, November 13, 2019

Certain E. faecalis strains secrete a substance called cytolysin, which is toxic to liver cells, killing them and thus damaging the liver.

Key Points: 
  • Certain E. faecalis strains secrete a substance called cytolysin, which is toxic to liver cells, killing them and thus damaging the liver.
  • Fecal samples from patients with alcoholic hepatitis had about 2,700-fold more E. faecalis than samples from controls.
  • The complete study, Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease, can be found in the November 21 issue of Nature.
  • The J. Craig Venter Institute (JCVI) is a not-for-profit research institute in Rockville, MD.